Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large events to stay on top of the most pressing changes. The past few years in ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...

Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies. Zachary Roberts joined ...